Replimune Group (NASDAQ:REPL) Shares Down 5.3% – Should You Sell?

Posted by Francis Steltz on Sep 5th, 2026

Replimune Group, Inc. (NASDAQ:REPL – Get Free Report)’s stock price traded down 5.3% during mid-day trading on Thursday . The company traded as low as $15.12 and last traded at $15.14. 763,180 shares traded hands during mid-day trading, a decline of 84% from the average daily volume of 4,804,738 shares. The stock had previously closed at $15.98.

Analyst Ratings Changes

REPL has been the topic of several research analyst reports. Wolfe Research upgraded Replimune Group to an “outperform” rating in a report on Tuesday, August 4th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Replimune Group in a research report on Wednesday, August 12th. Piper Sandler upgraded shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 31st. Weiss Ratings downgraded shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 11th. Finally, JPMorgan Chase & Co. upped their target price on shares of Replimune Group from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 26th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Replimune Group presently has a consensus rating of “Moderate Buy” and an average target price of $12.00.

Read Our Latest Research Report on Replimune Group

Replimune Group Stock Performance

The stock has a market capitalization of $1.41 billion, a price-to-earnings ratio of -4.77 and a beta of 0.94. The company has a debt-to-equity ratio of 1.00, a current ratio of 5.23 and a quick ratio of 5.23. The stock has a 50-day moving average of $12.25 and a 200 day moving average of $8.61.

Replimune Group (NASDAQ:REPL – Get Free Report) last released its earnings results on Friday, August 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). On average, analysts expect that Replimune Group, Inc. will post -2.81 EPS for the current year.

Insider Buying and Selling at Replimune Group

In other Replimune Group news, CEO Sushil Patel sold 39,341 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $510,252.77. Following the transaction, the chief executive officer directly owned 708,151 shares of the company’s stock, valued at approximately $9,184,718.47. This trade represents a 5.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Andrew Schwendenman sold 7,632 shares of Replimune Group stock in a transaction on Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $98,987.04. Following the sale, the chief accounting officer directly owned 99,425 shares of the company’s stock, valued at $1,289,542.25. This represents a 7.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 79,124 shares of company stock valued at $1,038,364 in the last three months. Insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

Several institutional investors have recently modified their holdings of the stock. BlackRock Inc. bought a new position in Replimune Group during the 2nd quarter worth approximately $99,171,000. RTW Investments LP increased its stake in Replimune Group by 11.6% in the fourth quarter. RTW Investments LP now owns 7,140,352 shares of the company’s stock valued at $69,404,000 after purchasing an additional 744,620 shares in the last quarter. Montanova Capital LLC raised its holdings in Replimune Group by 4.0% in the second quarter. Montanova Capital LLC now owns 4,389,836 shares of the company’s stock worth $48,595,000 after purchasing an additional 168,000 shares during the period. State Street Corp boosted its position in shares of Replimune Group by 26.3% during the fourth quarter. State Street Corp now owns 3,693,107 shares of the company’s stock worth $35,897,000 after purchasing an additional 768,982 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Replimune Group by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 3,479,395 shares of the company’s stock valued at $14,579,000 after buying an additional 9,707 shares during the period. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Company Profile

(Get Free Report)

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.